Clinical trial · Interventional
The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD)
THE Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to explore the PK/PD changes of NMN and DC cells after oral NMN combined with DC cells injection in patients after tumor surgery, and evaluate the biological age of adults, TCR diversity, SiRT1 expression level, SF-36 quality of life, OS, antigen specific immune response (TAA), cytokines and so on. In this study, 20 postoperative tumor patients who meet the entry and excretion criteria were recruited to explore the clinical potential of NMN combined with DC cell vaccine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Postoperative Prevention of Tumor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral NMN combined with DC cell vaccine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Orally take NMN (Vital NAD) combined with DC cell vaccine injection
- description
- The arm is a combination of two drugs. The first NMN is a precursor of NAD+, which is used orally. DC vaccine is a kind of immune cells expanded in vitro and used by injection.
- interventionNames
- Drug: Oral NMN combined with DC cell vaccine
Primary outcomes (10)
- measure
- Concentration of double antibodies in peripheral blood
- timeFrame
- Up to 3 months
- measure
- Concentration of NMN (nicotinamide mononucleotide) in peripheral blood
- timeFrame
- Up to 3 months
- measure
- Peripheral blood NAD+
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. 18-80 years old, weight ≥ 40kg. * 2\. Patients with malignant solid tumors diagnosed by histology or cytology, who underwent radical resection and completed standard postoperative adjuvant therapy. * 3\. Estimated survival time ≥ 6 months. * 4\. ECOG score 0-1. * 5\. Adequate venous channels, there is no contraindication for peripheral blood monocyte collection. * 6\. Good function of organs and bone marrow. Exclusion Criteria: * 1\. Diabetes. * 2\. Premenopausal or menopause \<1 year. * 3\. Persons who have received hormone replacement therapy within the past 6 months. * 4\. Persons who take vitamin B supplementation and are not willing to discontinue supplementation for 3 weeks before and during the entire study period. * 5\. Unstable weight (\>3% change during the last 2 months before entering the study). * 6\. Significant organ system dysfunction or disease. * 7\. Polycystic ovary syndrome. * 8\. Major psychiatric illness. * 9\. Use of medications known to affect study outcome measures (e.g., steroid) or increase the risk of study procedures (e.g., anticoagulants) that cannot be temporarily discontinued for the study. * 10\. Metal implants. * 11\. Persons who consume \>14 units of alcohol per week. * 12\. Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.
References
Publications (0)
Data not yet available